Onconetix (ONCO) Competitors $3.00 +0.07 (+2.22%) As of 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCO vs. JBIO, PMCB, PLRZ, THAR, PPBT, GTBP, VAXX, LIAN, KTTA, and VYNEShould you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Jade Biosciences (JBIO), Nuvilex (PMCB), Polyrizon (PLRZ), Tharimmune (THAR), Purple Biotech (PPBT), GT Biopharma (GTBP), Vaxxinity (VAXX), LianBio (LIAN), Pasithea Therapeutics (KTTA), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry. Onconetix vs. Its Competitors Jade Biosciences Nuvilex Polyrizon Tharimmune Purple Biotech GT Biopharma Vaxxinity LianBio Pasithea Therapeutics VYNE Therapeutics Jade Biosciences (NASDAQ:JBIO) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Which has stronger valuation & earnings, JBIO or ONCO? Onconetix has higher revenue and earnings than Jade Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJade BiosciencesN/AN/A-$69.63M-$30.33-0.25Onconetix$2.52M0.63-$58.69MN/AN/A Do analysts recommend JBIO or ONCO? Jade Biosciences currently has a consensus target price of $16.00, indicating a potential upside of 111.64%. Given Jade Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Jade Biosciences is more favorable than Onconetix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jade Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Onconetix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is JBIO or ONCO more profitable? Jade Biosciences has a net margin of 0.00% compared to Onconetix's net margin of -3,327.03%. Jade Biosciences' return on equity of -51.96% beat Onconetix's return on equity.Company Net Margins Return on Equity Return on Assets Jade BiosciencesN/A -51.96% -47.65% Onconetix -3,327.03%-160.51%-78.96% Does the media refer more to JBIO or ONCO? In the previous week, Jade Biosciences had 6 more articles in the media than Onconetix. MarketBeat recorded 10 mentions for Jade Biosciences and 4 mentions for Onconetix. Onconetix's average media sentiment score of 0.34 beat Jade Biosciences' score of -0.30 indicating that Onconetix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Onconetix 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, JBIO or ONCO? Jade Biosciences has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.37, indicating that its stock price is 237% more volatile than the S&P 500. Do institutionals and insiders have more ownership in JBIO or ONCO? 23.9% of Onconetix shares are owned by institutional investors. 24.9% of Jade Biosciences shares are owned by insiders. Comparatively, 3.1% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryJade Biosciences beats Onconetix on 8 of the 13 factors compared between the two stocks. Get Onconetix News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCO vs. The Competition Export to ExcelMetricOnconetixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.57M$3.13B$5.71B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E RatioN/A20.9230.9125.28Price / Sales0.63232.70404.2188.50Price / CashN/A41.5625.2228.45Price / Book0.279.779.536.01Net Income-$58.69M-$54.74M$3.26B$265.34M7 Day Performance5.46%8.37%4.66%2.89%1 Month Performance-12.94%7.94%5.35%1.61%1 Year Performance-99.49%18.27%32.14%25.61% Onconetix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOOnconetix0.9161 of 5 stars$3.00+2.2%N/A-99.5%$1.57M$2.52M0.0012Earnings ReportShort Interest ↓JBIOJade Biosciences2.2638 of 5 stars$7.41+0.1%$15.00+102.4%N/A$6.22MN/A-0.1220News CoveragePositive NewsEarnings ReportAnalyst DowngradeAnalyst RevisionPMCBNuvilex1.5279 of 5 stars$0.90+3.0%N/A-52.8%$6.19MN/A1.224News CoveragePositive NewsHigh Trading VolumePLRZPolyrizonN/A$1.00-2.9%N/AN/A$5.99MN/A0.00N/ATHARTharimmune3.4818 of 5 stars$1.39+16.2%$17.00+1,119.5%-54.2%$5.76MN/A-0.172Positive NewsEarnings ReportShort Interest ↓PPBTPurple Biotech2.2286 of 5 stars$2.22+0.7%$33.00+1,389.8%N/A$5.74MN/A-5.2720Gap DownGTBPGT Biopharma2.6206 of 5 stars$1.72-1.1%$11.00+539.5%-40.4%$5.63MN/A-0.308Earnings ReportVAXXVaxxinityN/A$0.04+42,900.0%N/A-57.0%$5.45MN/A-0.1090Gap DownLIANLianBioN/A$0.05flatN/A-82.4%$5.43MN/A-0.06110KTTAPasithea Therapeutics1.401 of 5 stars$0.70+3.0%N/A-84.9%$5.19MN/A-0.073Positive NewsEarnings ReportShort Interest ↓VYNEVYNE Therapeutics2.1773 of 5 stars$0.34-0.3%$6.25+1,738.2%-81.1%$5.19M$500K-0.3430Earnings Report Related Companies and Tools Related Companies JBIO Alternatives PMCB Alternatives PLRZ Alternatives THAR Alternatives PPBT Alternatives GTBP Alternatives VAXX Alternatives LIAN Alternatives KTTA Alternatives VYNE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCO) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access